Emergent BioSolutions' CEO Discusses Q2 2012 Results - Earnings Call Transcript

Emergent BioSolutions, Inc. (EBS)

Q2 2012 Earnings Conference Call

August 2, 2012 05:00 PM ET

Executives

Daniel J. Abdun-Nabi - President and CEO

R. Don Elsey - SVP Finance & Administration, and CFO

Adam R. Havey - EVP and President, BioDefense Division

W. James Jackson, Ph.D - SVP and Chief Scientific Officer

Robert Burrows - VP of Investor Relations

Analysts

Cory Kasimov - JP Morgan Chase & Co

Nicholas Bishop - Cowen and Company, LLC, Research Division

Mario Corso - Caris & Company

Matthew Miksic - Piper Jaffray & Co.

Presentation

Operator

Good day ladies and gentlemen and welcome to the Emergent BioSolutions Second Quarter of 2012 Financial Results Conference Call. My name is Ian and I will be your operator for today. At this time, all participants are in a listen-only mode. We will conduct a question-and-answer session towards the end of this conference. (Operator Instructions) And as a reminder, this call is being recorded for replay purposes.

I’d now like to turn the call over to Bob Burrows, Vice President of Investor Relations. Please proceed, sir.

Robert Burrows

Thank you, Ian. Good afternoon, ladies and gentlemen. Thank you for joining us today as we discuss Emergent BioSolutions second quarter of 2012 financial results.

As is customary, our call today is open to all participants. In addition, the call is being recorded and it’s copyrighted by Emergent BioSolutions. The call today will start with a brief prepared comments by our President and Chief Executive Officer, Dan Abdun-Nabi, who will give an overview of our financial performance for the second quarter, a brief business update and our 2012 forecast, including revenue expectations for the third quarter. Then, our CFO, Don Elsey will go through the financials in detail before we open up the call for your questions. We have several other members of senior management available to respond to your questions.

If you liked this article you might like

Biotech movers: Ionis Drops After GSK Bows Out of Partnership

Emergent BioSolutions (EBS) Highlighted As Weak On High Volume

New Lifetime High For Emergent BioSolutions (EBS)

New Lifetime High Reached By Emergent BioSolutions (EBS)

New Lifetime High Reached: Emergent BioSolutions (EBS)